Myh11 Lineage Corneal Endothelial Cells and ASCs Populate Corneal Endothelium

Bruce A. Corliss,¹ H. Clifton Ray,¹ Corbin Mathews,¹ Kathleen Fitzgerald,¹ Richard W. Doty,¹ Chris M. Smolko,¹ Hamzah Shariff,¹ Shayn M. Peirce,¹,² and Paul A. Yates¹,²

¹Biomedical Engineering, University of Virginia, Charlottesville, Virginia, United States
²Department of Ophthalmology, University of Virginia, Charlottesville, Virginia, United States

Corneal endothelial cell (CEC) layer resides in the innermost portion of the cornea and composed of a single layer of hexagonal cells connected by tight junctions.¹ CECs serve a critical role in maintaining hydration and exchanging nutrients between the anterior chamber and the outer layers of the cornea, including the outermost epithelium and intermediate stromal layer.²,³ Active transport of ions across the endothelium, paired with its semipermeable membrane, leads to the “pump-leak” mechanism,² where water is constantly cycled through the corneal cell layers. This cycling maintains optical transparency for the tissue, allowing light to pass through unimpeded to the retina and facilitates sight. With the absence of a blood vessel network in the cornea to provide metabolic support, the constant fluid cycling directed by the cornea endothelium is also responsible for delivering necessary nutrients to the outer cornea layers.²

Proper function of the corneal endothelium is critical for the homeostatic maintenance and function of the tissue, with deficient fluid flux leading to tissue dehydration and inadequate nutrient supply, whereas excess fluid flux leads to corneal edema and a reduction in visual acuity. To preserve function, CEC cell populations must remain at sufficient densities to maintain the basement membrane and outer tissue layers. However, previous research suggests that the CEC layer cannot be regenerated or repopulated in adult tissue, and CECs dropout with aging, injury, surgical trauma, and dysfunction,⁵ often requiring cornea transplant surgery.⁶ Disruption of this cell population can occur with various corneal diseases,⁷ hypoxia caused by long-term wear of contacts,⁸ and cornea transplant surgery.⁹ Paradoxically, corneal transplants are often the only therapeutic option for a depleted corneal endothelium, but the trauma from the surgical procedure can lead to further dropout of CECs.¹⁰ Transplant patients exhibit a 4-fold dropout of the CEC layer compared with uninjured corneas.¹¹ Without an endogenous cell population to repopulate this tissue layer, which is required for homeostatic maintenance of the cornea and critical for visual acuity, a clinically relevant exogenous cell population is needed to prevent attrition of this cell layer and preserve its function. Adipose-derived stromal cells (ASCs) represent a cell population that can be efficiently harvested in the clinic from readily available adipose tissue, cultured, and reintroduced into the patient as an autologous stem cell
therapy that avoids immune responses associated with use of exogenous tissue sources. We demonstrate that CECs share Myh11 transcriptional lineage with a subpopulation of ASCs, a marker previously associated only with vascular smooth muscle cells and pericytes, using a lineage tracing mouse model and confirmed with antibody immunofluorescence and Western blot. Informed by their shared transcriptional lineage, we demonstrate that cultured ASCs can differentiate into a phenotype associated with CECs and are capable of adhering to injured adult corneal endothelium when exogenously injected into the anterior chamber after a scratch injury. Whole tissue image analysis of corneas from Myh11 lineage tracing mice indicates that Myh11 exclusively marks a stable subpopulation of CECs and cells that express Myh11 may serve some unknown function in maintenance of the endothelium. We provide the first lineage tracing mouse model for selectively following a subset of endothelial cells in the cornea that can trace their cell fate in injury and disease, and demonstrate the potential to supplement the corneal endothelium with a clinically relevant cell source.

**Methods**

**Animals**

All surgical procedures were approved by the Institutional Animal Care and Use Committee at the University of Virginia and adhered to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. We generated Myh11-CreERT2 mice that were crossed with ROSA26-STOPFlx-eYFP/+ (stock number 006148; The Jackson Laboratory, Bar Harbor, ME, USA) and ROSA26-STOPFlx-dTomato+/+ (stock number 007914; The Jackson Laboratory) to generate Myh11-CreERT2; ROSA26-STOPFlx-eYFP+/+ (Myh11-eYFP) and Myh11-CreERT2; ROSA26-STOPFlx-dTomato+/+ (Myh11-RFP) mice. Mouse tissues were treated with tamoxifen as done previously (Supplementary Methods S1: Tamoxifen Treatment).

**Immunohistochemistry and Immunocytochemistry**

Immunostaining was carried out as done previously (Supplementary Methods S2: Immunofluorescence).

**5-Ethynyl-2'-Deoxuryidine (EdU) Assay**

To label proliferating cells in the cornea, we used 5-ethyl-2'-deoxuryidine (EdU) (A10044; ThermoFisher, Waltham, MA, USA) and Click-IT EdU AlexaFluor 647 Imaging Kit (C10340; ThermoFisher). Tamoxifen-induced Myh11-RFP adult male mice were intraperitoneally injected with 200 mg/kg EdU at 12 weeks of age to examine cell proliferation, with only a single injection used because higher concentrations can exhibit toxic effects. Thirty days after injection, corneas were harvested and fixed in 3,7% paraformaldehyde for 15 minutes at room temperature. Following fixation, corneas were washed with 3% BSA in PBS, and permeabilized with 0.5% Triton X-100 in PBS for 20 minutes at room temperature. The tissue was washed in 3% BSA in PBS. Corneas were incubated with Click-IT reaction cocktail (containing reaction buffer, CuSO4, Alexa Fluor 647 Azide, and reaction buffer additive) for 30 minutes at room temperature. Last, tissues were washed with 3% BSA for 30 minutes twice, and then stained for 4',6-diamidino-2-phenylindole (DAPI) and whole-mounted for confocal imaging.

**Primary Cell Culture**

Myh11-Lin(-) mural cells from the epididymal adipose tissue was harvested for collection and culturing by previous a previous protocol (Supplementary Methods S3: Primary Cell Culture).

**In Vitro CEC Differentiation**

Myh11-Lin(-) ASCs were uplifted and cultured on FNC Coating Mix (NC9971265; ThermoFisher). Once Myh11-Lin(-) ASCs reached greater than 90% confluency, the standard media was replaced by corneal endothelial differentiation media as previously described. Briefly, Myh11-Lin(-) ASCs were exposed for 3 days to dual Smad induction media, which consisted of Dulbecco's modified Eagle's medium (DMEM)/F12 supplemented with 20% KnockOut serum replacement (10828028; Thermofisher), 1% nonessential amino acids (11140076; ThermoFisher), 500 ng/mL Noggin (SRP3227; Sigma, St. Louis, MO, USA) 10 μM SB31542 (S4157; Sigma), 1 mM L-glutamine (25030081; Thermofisher), 0.1 mM betamercaptoethanol (21985023; Thermofisher), and 8 ng/mL recombinant murine FGF-2 (+50–53; PeproTech, Rocky Hill, NJ, USA). On day 3, the dual Smad induction media was replaced with dual Smad induction media supplemented with 0.1X B27 supplement (17504044; Thermofisher), 10 ng/mL recombinant mouse Dkk-2 (2435-DKB/CF; R&D Systems, Minneapolis, MN, USA), and 10 ng/mL recombinant murine PDGF-BB (315–18; PeproTech). This media solution was changed every 3 days over the course of 14 days. After the course of 14 days, cells were fixed and stained using methods described above.

**CEC In Vivo Injury Model**

We adopted a previous animal procedure to introduce injury to the CEC layer, followed by local delivery of Myh11-Lin(-) ASCs cultured in CEC-differentiated media for 14 days. Briefly, adult C57Bl/6j mice were placed under isoflurane anesthesia, and proparacaine hydrochloride ophthalmic solution was applied to the eyes as a topical anesthetic. Injury and injections were done on the right eye due to difficulty of angle and manipulation with one master-hand, and separate mice were given injury with injection of vehicle control. A small entry in the peripheral cornea was introduced with a 33-gauge needle. To induce injury and removal of CECs, a 36-gauge needle was used to scrape along the bottommost layer of the cornea, while avoiding the iris and lens. A total of 5000 Myh11-Lin(-) ASCs cultured in CEC-differentiation media were delivered in 3 μL of DMEM media supplemented with 100 μM Rho Kinase (ROCK) inhibitor Y27632 (Y0503; Sigma) and 100 μM TGFβR inhibitor SB431542 (S4317; Sigma). After the delivery of cells into the aqueous humor, the mice were immediately overturned on their backs tilted to lower the injected eye and allow the injected cells to settle toward the CEC layer and adhere. The mice were kept in isoflurane anesthesia for 3 hours to allow for cells to adhere to the CEC layer. Seven days after delivery of Myh11-CEC-differentiated cells, corneas were harvested and immunostained as described above.

**Immunoblotting**

Immunoblotting was performed as previously described (Supplementary Methods S4: Immunoblotting).

**Image Analysis and Statistical Analysis**

All data were processed using MATLAB (MathWorks, Natick, MA, USA) and ImageJ (http://imagej.nih.gov/ij/; provided in the
RESULTS

Myh11-Lin(+) Cells Are Exclusively Detected in the CEC Layer

Male Myh11-Cre-ERT2/loxP-Tomato mice were administered 2 weeks of intraperitoneal tamoxifen followed by a 4-week chase period, resulting in the labeling of Myh11 expressing cells with an RFP lineage marker. Myh11 expression has been claimed to be limited to only mural cells, and RFP+ cells were found as expected along the vasculature (not shown). However, examination of the cornea revealed quite unexpectedly RFP+ cells throughout the cornea (Fig. 1A). Male mice administered vehicle control did not show any RFP-expressing cells in the cornea, demonstrating that RFP expression was not due to leaky cre-recombinase with the mouse model, but rather specifically resulted from tamoxifen induction (Supplementary Fig. S1A). RFP+ cells, albeit at a lower cell density, were also observed in the cornea with 2 days of local administration of eyedrops containing 4-hydroxytamoxifen with 21 days of chase, suggesting these RFP+ cells were labeled locally and did not originate from the circulatory system (Supplementary Figs. S1B, S1C).

Confocal imaging of sagittally sectioned cornea layers revealed that these RFP-expressing cells were localized to the corneal endothelium (Fig. 1B). A high-resolution confocal z-stack visualized with a lateral projection of cornea (Fig. 1C), three-dimensional segmentation (Figs. 1D–G), and tissue layer-specific coronal z-projections (Figs. 1H–J) confirmed that RFP expression was exclusively found within the corneal endothelial layer. DAPI labeling confirmed confinement of RFP cells within a homogeneously spaced and highly organized cobblestone arrangement of cell nuclei, consistent with corneal endothelium.

Myh11-Lin(+) Cells in the Cornea Express Myh11 and Canonical CEC Markers

After establishing the existence of Myh11-lineage cells (Myh11-Lin(+)) in the CEC layer of adult Myh11-RFP mice, immunolabeling was used to characterize canonical CEC marker expression of Myh11-Lin(+) corneal cells and determine if Myh11 protein was actively produced and not merely the Myh11 transcript. Immunofluorescence revealed Myh11 expression not only in smooth muscle cells and pericytes along corneal limbal vessels, but also cells in the avascular CEC layer (Figs. 2A, 2B).

Expression of Myh11 protein in the cornea was confirmed with surgical isolation of avascular cornea from the vascularized limbal vessels and sclera through immunoblotting for Myh11 and CD31, a vascular endothelial cell marker. As expected with vascularized tissue, samples from sclera had detectable levels of Myh11 and CD31 (Fig. 2C). In contrast, samples isolated from cornea lacked CD31 expression, because no blood vessels exist within corneal tissue (Fig. 2D, t-test, \(P = 0.0062\)); however, corneal samples exhibited Myh11 expression at levels comparable to those found in the sclera (Fig. 2E, t-test, \(P = 0.357\)). Corneal Myh11-Lin(+) cells, labeled with RFP, were confirmed to exhibit the same marker expression as CECs,21–23 being positively marked with the junctional proteins N-cadherin and ZO-1, while lacking expression of CD31, CD34, and \(\alpha\)-smooth muscle actin (\(\alpha\)SMA) (Figs. 2F–H). The lack of vascular (CD31, CD34) and perivascular (\(\alpha\)SMA) markers lend further evidence that these corneal Myh11-Lin(+) cells are not affiliated with vascular cells and represent a distinct cell type from pericytes and smooth muscle cells.

Myh11-Lin(+) CECs Do Not Migrate Into the Central CEC Layer

Although the Myh11-Lin(+) cells in the CEC layer express Myh11 transcript and protein, and exhibit a CEC phenotype, there remains the possibility that a portion of these cells are perivascular in origin, having migrated from limbal vessels and scleral vasculature. If these cells are indeed migrating from the peripheral cornea, Myh11-Lin(+) cell density should change over time as more induced RFP+ cells migrate from peripheral to central cornea. At early timepoints, RFP+ cell density should be higher in the peripheral cornea compared with central, showing a negative slope in radial density of RFP+ cells toward the center of the cornea. We examined multiple timepoints following acute tamoxifen induction using eyedrops or intraperitoneal injection. High-resolution images of the entire cornea were automatically segmented to separate out nuclei of the CEC layer and determine CEC expression of RFP (Supplementary Fig. S2).

Tamoxifen eyedrops were administered over a 12-hour period followed by a short-term 12-hour chase period. Corneas were then harvested and RFP+ cell location was quantified relative to radial distance from the corneal center (radial densities were normalized to area of each bin). A positive slope was found across the 95% confidence interval, strongly suggesting that Myh11-Lin(+) cells did not migrate from the edge of the cornea (radial value of 0) to its center (radial value of 1) (Supplementary Fig. S3, 95% confidence interval of slope in brackets with best fit of linear model). Eye drop induction for 3 days with a 2-day or 21-day chase revealed no difference in the total number of Myh11-Lin(+) cells (Fig. 3A, t-test, \(P = 0.411\)). Both timepoints showed a slightly positive slope using a linear model mapping the fraction of RFP+ CECs to the radial distance from the peripheral cornea (Figs. 3B–E).

The same trends were observed in lineage-traced mice treated with 2 weeks of intraperitoneal injections of tamoxifen at 6 weeks and 16 weeks of age, both with 4 weeks of chase time after induction. There was no change in total number of Myh11-Lin(+) cells, and both timepoints had a positive relation between the fraction of marked cells and radial distance from center of the cornea (Figs. 4A–E). These findings across multiple timepoints strongly suggest RFP+ CEC distribution does not vary according to time from induction. There was an estimated 10-fold difference between RFP+ cell density between eyedrops of 4-hydroxytamoxifen and intraperitoneal injection of tamoxifen, but we attribute it to differences in the efficacy and duration of tamoxifen delivery.

Myh11-Lin(+) CECs are Slow-Cycling or Nonproliferative

There is sparse evidence to suggest that CECs proliferate in vivo, with one report suggesting that human adult corneas may contain proliferating CECs in the extreme periphery of the cornea. Importantly, this study was done using an explant model, which may present unique environmental conditions and cell behaviors as compared with in vivo.24 Adult tamoxifen-induced Myh11-RFP mice were intraperitoneally injected with 200 mg/kg of EdU, and after 30 days, we harvested the cornea tissue to investigate the proliferation of Myh11-Lin(+) CECs. As expected, EdU was detected in the proliferating corneal epithelial cells25; however, we did not find EdU labeling in Myh11-Lin(+) CECs or any other RFP-CECs.
**FIGURE 1.** Myh11 lineage tracing marks a subpopulation of cells on the basal surface of the cornea. (A) Confocal tile of the cornea of Myh11-Lin(+) male mice treated with 2 weeks of tamoxifen intraperitoneal injections with a 4-week chase, showing RFP lineage-labeled cells (red) and DAPI-labeled cell nuclei (blue). Scale bar: 1 mm. (B) Sagittal cryosection of cornea including the epithelial cell layer, stroma, and endothelial layer annotated from cell nuclei structure, with RFP-labeled lineage cells restricted to the endothelial layer. Scale bar: 50 μm. (C) Lateral maximum intensity projection of high-resolution confocal z-stack through cornea. Scale bar: 25 μm. (D) Three-dimensional reconstruction of cell nuclei, with clear separation of (E, H) epithelial, (F, I) stromal, and (G, J) endothelial cell layers delineated by cell nuclei structure and morphology. Scale bar: 25 μm.
Unlike what has been observed in other preclinical models, our results corroborate with the consensus finding that in adult murine tissue, healthy CECs are slow cycling or nonproliferating.

Cultured Myh11-Lin(+) ASCs Differentiate Into CEC-like Cells

Restoration of the corneal endothelium has previously been achieved by intraocular delivery of exogenous cells. Multipotent adult stromal cells may offer the potential for generating autologous CECs that would be resistant to rejection, and adipose tissue in particular offers a plentiful supply of such cells that can be easily harvested from patients. We explored the potential of using ASC-derived CECs to populate damaged endothelium.

Fortuitously, Myh11+ mural cells are suggested to be putative ASCs, and it is possible that the shared transcriptional Myh11 lineage may be favorable in restoring the corneal endothelium. ASCs were isolated by collecting yellow fluorescent protein

(Supplementary Fig. S4). Unlike what has been observed in other preclinical models, our results corroborate with the consensus finding that in adult murine tissue, healthy CECs are slow cycling or nonproliferating.

Cultured Myh11-Lin(+) ASCs Differentiate Into CEC-like Cells

Restoration of the corneal endothelium has previously been achieved by intraocular delivery of exogenous cells. Multipotent adult stromal cells may offer the potential for generating autologous CECs that would be resistant to rejection, and adipose tissue in particular offers a plentiful supply of such cells that can be easily harvested from patients. We explored the potential of using ASC-derived CECs to populate damaged endothelium.

Fortuitously, Myh11+ mural cells are suggested to be putative ASCs, and it is possible that the shared transcriptional Myh11 lineage may be favorable in restoring the corneal endothelium. ASCs were isolated by collecting yellow fluorescent protein
(YFP)-labeled Myh11-Lin(+) mural cells from the epididymal fat pad using enzymatic digestion, followed by fluorescence-activated cell sorting on YFP expression and immediate culturing of these sorted cells. Once near-confluent, YFP+ ASCs were cultured in a Smad inhibitor–based CEC differentiation media that has been previously used to induce CEC markers in human embryonic stem cells.18 After culturing YFP+ ASCs for 3 days in CEC differentiation media treatment, Western blot analysis (Fig. 5A) indicated a reduction in expression of the fibroblast marker HSP9029 (Fig. 5B, unpaired t-test, P = 0.0396) and a slight trend of lower αSMA expression (Fig. 5C, paired t-test, P = 0.298). Myh11-Lin(-)–derived ASCs did not initially express N-cadherin before treatment with CEC differentiation media (Fig. 5D), but they acquired expression after 14 days of treatment (Fig. 5E). During this time in culture, Myh11-Lin(+)–derived ASCs underwent morphological changes from an elongated, spindle-shaped fibroblast shape to a smaller, round phenotype.

Local Delivery of Differentiated Myh11-Lin(+) ASCs Into Injured CEC Layer

We next tested whether CECs derived in vitro from Myh11-Lin(+) ASCs could be exogenously delivered intraocularly and incorporated into the corneal endothelium. After introducing mechanical injury to the CEC layer of C57Bl/6j mice using an established protocol,19 we injected 5000 CEC-differentiated Myh11-Lin(+) ASCs into the anterior chamber of the eye; 100 μM of Rho Kinase (ROCK) inhibitor, Y-27632, and 100 μM TGFβR inhibitor, SB4314542, were coinjected to improve the engraftment of these exogenous cells.19 Immediately after injection, mice were positioned so that the anterior segment of the eye faced downward to promote adherence of injected cells to the CEC layer. One week after local delivery of these Myh11-Lin(+) ASC-derived CECs, we examined adherence and incorporation of these cells to the corneal endothelium. YFP+ labeled cells were found adherent to the corneal endothelial cell layer at the site of the injury and continued to express N-cadherin (Fig. 5F), but incorporation overall was less than 1% of injected cells. The results demonstrate it is feasible for Myh11+- ASC-derived CECs to be targeted to the corneal endothelium, but low incorporation rates and potential phenotypic differences from surrounding endogenous CECs suggest additional refinement to technique is needed to establish this cell source as a viable therapeutic.
DISCUSSION

The corneal endothelium is responsible for maintaining optical transparency and nutrient transport for the entire cornea, with CEC loss or dysfunction leading to significant visual impairment that often requires surgical intervention with donor CECs to correct. However, study of individual CEC cell fate has been limited due to the lack of appropriate animal models. We demonstrate for the first time that Myh11 is a marker for a subset of CECs, and show that Myh11 expression can be used in both a temporal and spatial manner to lineage trace CECs to examine their behavior in both healthy and diseased states. Using this model, we show there is no evidence for directional migration of labeled CECs in adult murine corneal tissue. We also show no evidence for acute proliferation of the Myh11 subset of CECs. We further anticipate such a lineage marker could be used to examine the CEC pool to provide additional insight into both embryonic and neonatal development of the cornea. Finally, we suspect that the Myh11 subset of CECs may represent a unique and previously unknown class of CECs that may have functional importance in endothelium maintenance, considering the established functions of Myh11 in mural cells on the vasculature.

Myh11 has been traditionally thought of as a specific and exclusive marker for vascular smooth muscle cells and pericytes, or mural cells that enwrap and regulate the macro- and microvasculature through contraction, juxtracrine, and paracrine signaling. It remains an open question whether there are functional parallels of Myh11 expression in regulating CEC function, given that Myh11 is a major contractile protein in pericytes. Intriguingly, Myh11+ CECs lack αSMA expression, with high αSMA expression as a defining characteristic of mural cells. Nevertheless, cytoskeletal complexes and other actomyosin proteins are heavily concentrated at the apical tight junctions and adherent junctions that form CEC barrier, and are implicated in the maintenance of CEC barrier integrity. Thus, Myh11 may play a key role in regulating CEC permeability through the activation of actomyosin pathways.

Compared with the epithelial and stromal layers, the CEC layer appears to have no regenerative capacity, with substantial evidence pointing to a complete lack of cell turnover, even in the case of acute injury. Accelerated degeneration of the corneal endothelium remains a substantial risk for any of the...
annual worldwide 185,000 corneal transplants, although cornea transplantation remains the only successful option to partially restore the cornea endothelium. Transplant procedures involve either the replacement of all cornea layers or just the CEC layer and the adjacent basement membrane. These partial transplants use donor CECs in Descemet’s membrane endothelial keratoplasty and Descemet’s stripping automated endothelial keratoplasty (DSAEK) grafts to replace lost and damaged CECs. However, exogenous cell sources are known to illicit a host immune response, possibly leading to graft rejection, impaired recovery, or a lack of visual acuity improvement. With only 1 in 70 patients in need of corneal transplants actually receiving a graft, there is a chronic shortage of donor tissue to meet global demands.

The use of autologous cell sources for these procedures have the possibility of providing superior clinical outcomes compared with allogeneic transplants, specifically with improved rate of recovery and less likelihood of rejection. Previous work has shown that human umbilical cord–derived stem cells can differentiate into CECs in vitro using differentiation media that alter TGFβ and bone morphogenetic protein signaling. Yet this stem cell source cannot be harvested from adult patients, limiting its utility for large-scale use in the clinic.

ASCs can be harvested in abundance from adult adipose tissue, a readily available adult tissue stem cell source. ASCs also have been shown to have in vitro differentiation capability similar to umbilical cord stem cells. We investigated a specific subpopulation of ASCs, those that express Myh11, and demonstrated they share transcriptional lineage with a subpopulation of CECs, which may possibly confer improved function. The adherence of CEC-differentiated Myh11-Lin(+) ASCs to the corneal endothelial surface demonstrates the concept of using an autologous stem cell therapy to regenerate the corneal endothelium, but clearly significant refinement is needed. It may be possible to improve engraftment by preparing a substrate on which CEC-differentiated Myh11-Lin(+) ASCs can be grown, allowing for an artificial autologous DSAEK transplant. Future work needs to address maintenance of the CEC phenotype for CEC-differentiated ASCs, improving conditions for engraftment, along with determining the degree
of therapeutic effect of these engineered cells on the recovery of injured corneal endothelium.

Acknowledgments

The authors thank the University of Virginia’s Advanced Microscopy Facility for their assistance with confocal imaging. Supported by the Hartwell Foundation and National Institutes of Health RO1EY022063-04 (SMP, PAY).

Disclosure: B.A. Corliss, None; H.C. Ray, None; C. Mathews, None; K. Fitzgerald, None; R.W. Doty, None; C.M. Smolko, None; H. Shariff, None; S.M. Peirce, None; P.A. Yates, RetiVue, LLC (E, I), Genetech/Roche (C)

References

1. Doughty MJ. Concerning the symmetry of the “hexagonal” cells of the corneal endothelium. Exp Eye Res. 1992;55:145–154.
2. Bonanno JA. Molecular mechanisms underlying the corneal endothelial pump. Exp Eye Res. 2012;95:2–7.
3. Miller WL. Cornea: fundamentals, diagnosis and management. Optom Vis Sci. 2018;95:625.
4. Zavala J, López Jaime GR, Rodríguez Barrientos CA, Valdez-Garcia J. Corneal endothelium: developmental strategies for regeneration. Eye. 2013;27:579–588.
5. Nucci P, Brancato R, Mets MB, Shevell SK. Normal endothelial cell density range in childhood. Arch Ophthalmol. 1990;108:247–248.
6. Agarwal A, Jacob S, Agarwal A, Agarwal S, Kumar MA. Iatrogenic descemetochorioretinopathy as a complication of phacoemulsification. J Catarract Refract Surg. 2006;32:895–897.
7. Bourne WM. Biology of the corneal endothelium in health and disease. Eye. 2003;17:912–918.
8. Carlson KH, Ilstrup DM, Bourne WM, Dyer JA. Effect of silicone elastomer contact lens wear on endothelial cell morphology in aphakic eyes. Cornea. 1990;9:45–47.
9. Boynton GE, Woodward MA. Evolving techniques in corneal transplantation. Curr Surg Rep. 2015;3:2.
10. Bourne WM, Brubaker RF, O’Fallon WM. Use of air to decrease endothelial cell loss during intraocular lens implantation. Arch Ophthalmol. 1979;97:1473–1475.
11. Bourne WM, Nelson LR, Hodge DO. Continued endothelial cell loss ten years after lens implantation. Ophthalmology. 1994;101:1014–1022; discussion 1022–1023.
12. Alagesan S, Griffins MD. Autologous and allogeneic mesenchymal stem cells in organ transplantation: what do we know about their safety and efficacy? Curr Opin Organ Transplant. 2014;19:65–72.
13. Chasseigneaux S, Moraca Y, Cochois-Guégan V, et al. Isolation and differential transcriptome of vascular smooth muscle cells and mid-capillary pericytes from the rat brain. Sci Rep. 2018;8:12272.
14. Berthiaume AA, Grant RI, McDowell KP, et al. Dynamic remodeling of pericytes in vivo maintains capillary coverage in the adult mouse brain. Cell Rep. 2018;22:8–16.
15. Hess DL, Kelly-Goss MR, Cherepanova OA, et al. Perivascular cells-specific knockout of the stem cell pluripotency gene Oct4 inhibits angiogenesis. Nat Commun. 2019;10:907.
16. Ligasová A, Strunin D, Friedecký D, Adam T, Koberna K. A fat cell death: a thymidine synthase inhibitor with DNA damaging activity. PLoS One. 2015;10:1–21.
17. Seeman SA, Tannan SC, Cao Y, Peirce SM, Lin KY. Differential effects of processing time and duration of collagenase digestion on human and murine fat grafts. Plast Reconstr Surg. 2015;136:189–199.
18. McCabe KL, Kunzevitzky NJ, Chiswell BP, Xia X, Goldberg JL, Lanza R. Efficient generation of human embryonic stem cell-derived corneal endothelial cells by directed differentiation. PLoS One. 2015;10:1–24.
19. Okumura N, Sakamoto Y, Fujii K, et al. Rho kinase inhibitor enables cell-based therapy for corneal endothelial dysfunction. Sci Rep. 2016;6:21113.
20. James KA. An analysis of critical factors for quantitative immunoblotting. Sci Signal. 2015;8:1–12.
21. He Z, Forest E, Gain P, et al. 3D map of the human corneal endothelial cell. Sci Rep. 2016;6:29047.
22. Espana EM, Sun M, Birk DE. Existence of corneal endothelial slow-cycling cells. Invest Ophtalmol Vis Sci. 2015;56:3827–3837.
23. Fabiani C, Barabino S, Rashid S, Dana MR. Corneal epithelial regeneration using mesenchymal stem cells derived from human umbilical cord. Stem Cells Dev. 2018;27:1097–1108.
24. Joyce NC, Harris DL, Markov V, Zhang Z, Saitta B. Potential of human umbilical cord blood mesenchymal stem cells to heal damaged corneal endothelium. Mol Vis. 2012;18:547–564.
25. Dykstra JA, Facile T, Patrick RJ, et al. Concise review: fat and furious: harnessing the full potential of adipose-derived stromal vascular fraction. Stem Cells Transl Med. 2017;6:1096–1108.
26. Sontake V, Wang Y, Kasam RK, et al. Hsp90 regulation of fibroblast activation in pulmonary fibrosis. JCI Insight. 2017;2:e91454.
27. Fischbarg J. Mechanism of fluid transport across corneal endothelium and other epithelial layers: a possible explanation based on cyclic cell volume regulatory changes. Br J Ophtalmol. 1997;81:85–89.
28. Gomez D, Shankman LS, Nguyen AT, Owens GK. Detection of histone modifications at specific gene loci in single cells in histological sections. Nat Methods. 2013;10:171–177.
29. Gorovoy MS. Descemet-stripping automated endothelial keratoplasty. Cornea. 2006;25:886.
30. Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Ophthalmology. 1994;101:1536–1547.
31. Saba N, Abraham R, Keating A. Overview of autologous stem cell transplantation. Crit Rev Oncol Hematol. 2000;36:27–48.
32. Minter D, Marra KG, Rubin JP. Adipose-derived mesenchymal stem cells: biology and potential applications. In: Weyand B, Dominici M, Hass R, Jacobs R, Kasper C, eds. Mesenchymal Stem Cells – Basics and Clinical Application I. Advances in Biomedical Engineering/Biotechnology. Berlin: Springer Berlin Heidelberg; 2013:59–71.
33. Srivastav SP. Dynamic regulation of barrier integrity of the corneal endothelium. Optom Vis Sci. 2010;87:E239–E254.
34. Ote Y, Nishida K. Corneal regenerative medicine. Regen Tber. 2016;5:40–45.
35. Gain P, Julienne R, He Z, et al. Global survey of corneal transplantation and eye banking. JAMA Ophthalmol. 2016;134:167–173.